Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for pediatric ICU delirium
IRCT20250611066179N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of risperidone in delirium (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Length of hospitalization, Length of oxygen and 6 more. Started Oct 2025; status: completed.
02
Drugs
risperidone
03
Conditions
delirium
Beyond the preview
Go deeper on IRCT20250611066179N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250611066179N1.